BridgeBio is demonstrably improved the course of the new therapy for cardiac amyloidosis, utilizing the compound. Early patient information reveals promising benefits for patients diagnosed by this serious illness. The emphasis underscores BridgeBio's focus to treating significant patient needs in this heart disease arena. Attruby: BridgeBio's Nov